Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

References for PMC Articles for PubMed (Select 20660677)

1.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Jacobson JM, Thompson MA, Lalezari JP, Saag MS, Zingman BS, D'Ambrosio P, Stambler N, Rotshteyn Y, Marozsan AJ, Maddon PJ, Morris SA, Olson WC.

J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.

2.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD; AIDS Clinical Trials Group A5211 Team.

J Infect Dis. 2009 Dec 1;200(11):1724-8. doi: 10.1086/648090.

3.

A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.

Pett SL, McCarthy MC, Cooper DA, MacRae K, Tendolkar A, Norris R, Strizki JM, Williams KM, Emery S.

Antivir Ther. 2009;14(1):111-5.

PMID:
19320244
4.

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31. doi: 10.1128/AAC.01057-08. Epub 2008 Dec 15.

5.

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. doi: 10.1128/AAC.01055-08. Epub 2008 Dec 15.

6.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

7.

Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, Murga JD, Pemrick SM, D'Ambrosio P, Michael M, Kroger H, Ly H, Rotshteyn Y, Buice R, Morris SA, Stavola JJ, Maddon PJ, Kremer AB, Olson WC.

J Infect Dis. 2008 Nov 1;198(9):1345-52. doi: 10.1086/592169.

8.

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.

Schürmann D, Fätkenheuer G, Reynes J, Michelet C, Raffi F, van Lier J, Caceres M, Keung A, Sansone-Parsons A, Dunkle LM, Hoffmann C.

AIDS. 2007 Jun 19;21(10):1293-9.

PMID:
17545705
9.

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM.

Clin Infect Dis. 2007 Feb 15;44(4):591-5. Epub 2007 Jan 17. Erratum in: Clin Infect Dis. 2007 May 15;44(10):1399.

10.

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, Chappey C, Kiss LD, Paxinos EE, Petropoulos CJ.

Antimicrob Agents Chemother. 2007 Feb;51(2):566-75. Epub 2006 Nov 20.

11.

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC.

Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.

12.

Biology of CCR5 and its role in HIV infection and treatment.

Lederman MM, Penn-Nicholson A, Cho M, Mosier D.

JAMA. 2006 Aug 16;296(7):815-26. Review.

PMID:
16905787
13.

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E.

Nat Med. 2005 Nov;11(11):1170-2. Epub 2005 Oct 5.

PMID:
16205738
14.

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.

Lalezari J, Thompson M, Kumar P, Piliero P, Davey R, Patterson K, Shachoy-Clark A, Adkison K, Demarest J, Lou Y, Berrey M, Piscitelli S.

AIDS. 2005 Sep 23;19(14):1443-8.

PMID:
16135896
15.

Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, Asselin JJ, Cheung PK, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2005 Aug 1;192(3):466-74. Epub 2005 Jun 23.

16.

Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).

Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.

Virology. 2005 Jul 20;338(1):182-99.

17.

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection.

Moyle GJ, Wildfire A, Mandalia S, Mayer H, Goodrich J, Whitcomb J, Gazzard BG.

J Infect Dis. 2005 Mar 15;191(6):866-72. Epub 2005 Feb 11.

18.

Where does HIV live?

Stebbing J, Gazzard B, Douek DC.

N Engl J Med. 2004 Apr 29;350(18):1872-80. Review. No abstract available.

PMID:
15115833
19.

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP.

J Virol. 2004 Mar;78(6):2790-807. Erratum in: J Virol. 2005 Jun;78(12):6706.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk